“STUDY ON SAFETY AND EFFECTIVENESS OF ORAL TOFACITINIB IN PATIENTS WITH REFRACTORY MODERATE TO SEVERE ATOPIC DERMATITIS”, Int. Res. J. Pharm., vol. 9, no. 8, pp. 125–128, Aug. 2018, doi: 10.56802/gzfvmr94.